TITLE

PHARMASSET TO DEVELOP CLEVUDINE FOR HEPATITIS B

PUB. DATE
August 2005
SOURCE
Worldwide Biotech;Aug2005, Vol. 17 Issue 8, p5
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the license agreement of Pharmasset Inc. with Bukwang Pharmaceutical Co. Ltd., to develop and commercialize Clevudine, a treatment for hepatitis B virus infections, as of August 2005. Product details; Terms of the agreement; Background information on Pharmasset.
ACCESSION #
17732356

 

Related Articles

  • Pharmasset Starts Phase III Trial Of Clevudine.  // Bioworld Week;10/8/2007, Vol. 15 Issue 41, p3 

    The article reports on the commencement of the Phase III clinical trial of Pharmasset Inc.'s pyrimidine nucleoside analogue Clevudine in the U.S. The company has acquired $1 million as a payment from Korean partner Bukwang Pharmaceutical Co. Ltd. The 48-week evaluation aims to identify the...

  • Alnylam and Arrowhead Form Collaboration and Licensing Agreement.  // Biomedical Market Newsletter;1/7/2012, Vol. 21, p1 

    The article offers information on a collaboration and joint licensing agreement between Alnylam Pharmaceuticals Inc. and Arrowhead Research Corp. In this collaboration, Alnylam Pharmaceuticals, a RNAi therapeutics company, has provided license to Arrowhead Researc under its intellectual property...

  • Coming Monday in BioWorld Insight.  // BioWorld Today;3/22/2013, Vol. 24 Issue 55, p8 

    The article presents an overview of topics that will be featured in the March 25, 2013 issue of "BioWorld Insight," including early warning signs to combat emerging diseases, a licensing agreement entered by Galena Biopharma Inc. and an online course about epidemics.

  • Other News To Note.  // BioWorld Today;1/19/2012, Vol. 23 Issue 12, p2 

    This section offers news briefs on the biopharmaceutical industry. An exclusive licensing agreement was signed between Applied Pharma Research SA and Labtec GmbH for the marketing and distribution of Setofilm. An orphan drug designation was granted by the European Medicines Agency (EMA) to...

  • DuPont Makes Moves To Boost Life Sciences.  // Chemical Market Reporter;10/04/99, Vol. 256 Issue 14, p18 

    Focuses on the research collaboration and a licensing agreement formed by E.I. du Pont de Nemours & Co. with Pharmasset Ltd. Focus of the collaboration; Other agreement formed by DuPont Pharmaceuticals.

  • Infectious Diseases News Round-up.  // PharmaWatch: Monthly Review;Oct2007, Vol. 6 Issue 10, p22 

    The article offers news briefs in the pharmaceutical industry. Sinovac Biotech Ltd. has started vaccination of volunteers for a clinical trial of its pandemic avian influenza vaccine. Pharmasset Ltd. has reported preliminary safety and potent antiviral activity with its investigational drug...

  • Prevalence and Clinical Correlates of YMDD Variants during Lamivudine Therapy for Patients with Chronic Hepatitis B.  // Clinical Infectious Diseases;3/15/2003, Vol. 36 Issue 6, p687 

    YMDD variants of hepatitis B virus (HBV) emerge in some patients with chronic hepatitis B who receive lamivudine. YMDD variants were examined in 794 patients in 4 controlled studies of 1 year's duration. The long-term effects of YMDD variants were examined in a subset of patients treated up to 4...

  • Molecular Therapeutics of HBV. Ruian Xu; Kexia Cai; Dexian Zheng; Hong Ma; Sue Xu; Sheung-tat Fan // Current Gene Therapy;Aug2003, Vol. 3 Issue 4, p341 

    The hepatitis B virus (HBV) infection is a public health problem worldwide, particularly in East Asia. The current therapy of HBV infection is mostly based on chemical agents and cytokines that have been shown to provide limited efficacy and are also toxic to the human body. Gene therapy is a...

  • Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment. F. Moriconi; P. Colombatto; B. Coco; P. Ciccorossi; F. Oliveri; D. Flichman; A. M. Maina; R. Sacco; F. Bonino; M. R. Brunetto // Journal of Antimicrobial Chemotherapy (JAC);Aug2007, Vol. 60 Issue 2, p341 

    Objectives We studied the impact of hepatitis B virus (HBV) polymerase/reverse transcriptase (Pol/Rt) heterogeneity on adefovir rescue therapy in 34 consecutive chronic hepatitis B patients with viral breakthrough during lamivudine monotherapy. Methods The Pol/Rt A–F domains were...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics